Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology
The Pharma Data
NOVEMBER 29, 2020
MDM2 is a key regulator of the tumor suppressor p53 and one of the most potent inhibitors of apoptosis discovered thus far. 2017, 16 , 101-114. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. 2015, 58 , 1038?1052.
Let's personalize your content